Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4295909 | 0.84 | MPI (0.35) | — | |
| SCHEMBL16703164 | 0.84 | MPI (0.35) | — | |
| SCHEMBL17941696 | 0.81 | MPI (0.36) | — | |
| SCHEMBL7154573 | 0.76 | PAX8 (0.38) | PAX8 | |
| SCHEMBL7154576 | 0.76 | PAX8 (0.38) | PAX8 | |
| SCHEMBL1651731 | 0.76 | LMNA (0.44) | PAX8 | |
| SCHEMBL2704166 | 0.75 | PAX8 (0.32) | PAX8 | |
| SCHEMBL166837 | 0.75 | PAX8 (0.32) | PAX8 | |
| SCHEMBL19295 | 0.75 | PAX8 (0.32) | PAX8 | |
| SCHEMBL3486713 | 0.75 | LMNA (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116003487-A | Oligonucleotide conjugate, preparation method and application thereof | 苏州时安生物技术有限公司 | 2023-04-25 | — | — | CN | disclosed |
| US-20220275366-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA) | BANK OF AMERICA, N.A. | 2022-09-01 | — | — | US | disclosed |
| US-20220056441-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA) | SIRNA THERAPEUTICS INC (US) | 2022-02-24 | — | — | US | disclosed |
| US-10889815-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-10662428-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190233821-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | BANK OF AMERICA, N.A. | 2019-08-01 | — | — | US | disclosed |
| US-10351852-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20190194658-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | SIRNA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20190010497-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | SIRNA THERAPEUTICS INC (US) | 2019-01-10 | — | — | US | disclosed |
| US-20180245083-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | SIRNA THERAPEUTICS INC (US) | 2018-08-30 | — | — | US | disclosed |
| US-20060217334-A1 | Synthesizing a double stranded nucleic acid molecule used for treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability | SIRNA THERAPEUTICS, INC. (US) | 2006-09-28 | — | — | US | disclosed |
| EP-1627061-A2 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | Sirna Therapeutics, Inc. (US) | 2006-02-22 | — | — | EP | disclosed |
| EP-1622572-A2 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | Sirna Therapeutics, Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2005041859-A2 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY. | SIRNA THERAPEUTICS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005019453-A2 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050032733-A1 | siNA molecule comprising a double-stranded structure that down-regulates expression of Hepatitis B Virus (HBV) , wherein said siNA molecule does not require the presence of nucleotides having a 2'-hydroxy group within the siNA molecule for mediating RNA interference | SIRNA THERAPEUTICS, INC. (US) | 2005-02-10 | — | — | US | disclosed |
| US-20050020525-A1 | first nucleotide sequence complementary to a target RNA sequence or a portion thereof, and a second sequence chemically modified so that it can no longer act as a guide sequence for mediating RNA interference, having complementarity to said first sequence; pharmaceutical use such as viricide | SIRNA THERAPEUTICS, INC. | 2005-01-27 | — | — | US | disclosed |
| US-20040249178-A1 | Biological conjugates used for drug delivery; side effect reduction | SIRNA THERAPEUTICS, INC. (US) | 2004-12-09 | — | — | US | disclosed |
| US-20040192626-A1 | siNA molecule comprising a double-stranded structure that down-regulates expression of a target nucleic acid, wherein said siNA molecule does not require a 2'-hydroxyl group containing ribonucleotide; treating viral diseases such as SARS (severe acute respiratory syndrome virus), herpes, hepatitis, HIV | BANK OF AMERICA, N.A. | 2004-09-30 | — | — | US | disclosed |
| US-20040110296-A1 | biological conjugates used for drug delivery; side effect reduction | RIBOZYME PHARMACEUTICALS, INC. | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192626-A1 | siNA molecule comprising a double-stranded structure that down-regulates expression of a target nucleic acid, wherein said siNA molecule does not require a 2'-hydroxyl group containing ribonucleotide; treating viral diseases such as SARS (severe acute respiratory syndrome virus), herpes, hepatitis, HIV | SARS1, EIF2AK2, MAVS | PAX8 4011/4885 |
| US-10662428-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | AGO2, SNRPE, SRRT | PAX8 4115/4885 |
| US-20050020525-A1 | first nucleotide sequence complementary to a target RNA sequence or a portion thereof, and a second sequence chemically modified so that it can no longer act as a guide sequence for mediating RNA interference, having complementarity to said first sequence; pharmaceutical use such as viricide | AGO2, SRRT, ADAR | PAX8 4440/4885 |
| US-20220275366-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA) | AGO2, SRRT, SNRPE | PAX8 4489/4885 |
| US-20190010497-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | AGO2, SNRPE, SRRT | PAX8 4115/4885 |
| US-20060217334-A1 | Synthesizing a double stranded nucleic acid molecule used for treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability | SNRPE, MSI2, AGO2 | PAX8 1181/4885 |
| US-20190194658-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | AGO2, SNRPE, SRRT | PAX8 4115/4885 |
| US-20040249178-A1 | Biological conjugates used for drug delivery; side effect reduction | ALB, HEXA, ADAR | PAX8 4535/4885 |
| US-20040110296-A1 | biological conjugates used for drug delivery; side effect reduction | ALB, HEXA, ADAR | PAX8 4535/4885 |
| US-10889815-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | AGO2, SNRPE, SRRT | PAX8 4115/4885 |
| US-20050032733-A1 | siNA molecule comprising a double-stranded structure that down-regulates expression of Hepatitis B Virus (HBV) , wherein said siNA molecule does not require the presence of nucleotides having a 2'-hydroxy group within the siNA molecule for mediating RNA interference | SNRPE, SIN3A, SRRT | PAX8 3477/4885 |
| US-20220056441-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA) | AGO2, SNRPE, SRRT | PAX8 4115/4885 |
| US-20190233821-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | AGO2, SNRPE, SRRT | PAX8 4115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.